Trial | Design | Sample size | Age range (yrs) | Population characteristics | Duration | Intervention | Control | Outcomes | Jadad quality grades (0-5) |
---|---|---|---|---|---|---|---|---|---|
Ljunghall et al. (1987) | Parallel | 65 | 61-65 | Middle-aged men with impaired glucose tolerance; Swedish | 12 weeks | 0.75 ug alpha-calcidol, daily | placebo | TC, HDL, TG | 1 |
Heikkinen et al. (1997) | Parallel | 178 | 47-56 | Postmenopausal women; Finnish | 3 years | 300 IU cholecalciferol+500 mg calcium lactate, daily | 500 mg calcium lactate | TC, LDL, HDL, TG | 2 |
Pfeifer et al. (2001) | Parellel | 148 | 74 ± 1 | Elderly women with low vitamin D status; German | 8 weeks | 800 IU vitamin D3+1200 mg calcium, daily | 1200 mg calcium | TC | 4 |
Nagpal et al. (2009) | Parallel | 71 | ≥ 35 | Middle-aged healthy men with central obesity; Indian | 42 days | 120000 IU cholecalciferol, fortnightly | placebo | TC, LDL, HDL, TG | 5 |
Zittermann et al. (2009) | Parallel | 165 | 48 ± 10 | Healthy overweight subjects; German | 1 year | 3332 IU cholecalciferol, daily | placebo | LDL, HDL, TG | 5 |
Jorde et al. (a/b) (2010) | Parallel | 216/226 | 21-70 | Overweight and obese subjects; Norwegian | 1 year | 20000/40000 IU cholecalciferol weekly +500 mg calcium daily | 500 mg calcium | TC, LDL, HDL, TG | 4 |
Witham et al. (a/b) (2010) | Parallel | 40/39 | 65 ± 10 | Patients with type 2 diabetes; Scottish | 16 weeks | 100000/200000 IU vitamin D3, once | placebo | TC | 5 |
Witham et al. (2010) | Parallel | 58 | 67 ± 10 | Patients with a history of stroke; Scottish | 16 weeks | 100000 IU ergocalciferol once | placebo | TC | 5 |
Maki et al. (2011) | Parallel | 60 | 18-79 | Subjects with high waist circumference; American | 8 weeks | 1200 IU cholecalciferol+MVM (multivitamin and mineral), daily | MVM | TC, LDL, HDL, TG | 5 |
Sai et al. (2011) | Parallel | 213 | 65-77 | Postmenopausal women; American | 3 years | 0.5 ug calcitriol, daily | placebo | TC, LDL, HDL, TG | 4 |